Insights on Clinical Trials

  1. Closing The Readiness Gap For CGTs In Community-Based Care 6/11/2026

    Only one in five eligible cell and gene therapy patients receives treatment. Expanding access into community hospitals requires overcoming significant operational and readiness barriers.

  2. Demonstrating IDS Value With Time-Based Metrics 6/10/2026

    Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

  3. End-To-End Clinical, Biometrics, And Regulatory Support In Neurology 6/4/2026

    Discover how an integrated NDA strategy aligned data, vendors, and regulatory execution to achieve an on-time submission and approval without major FDA queries.

  4. Early Detection vs. Overdiagnosis: The ctDNA Screening Paradox 6/4/2026

    Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.

  5. Managing Supply Disruptions In ATIMP Clinical Trials 6/1/2026

    ATIMP trials leave little room for error. Learn how teams use contingency planning, real-time data, and AI to prevent supply disruptions.

  6. Executing Pediatric Gene Therapy Trials At The Site Level 5/29/2026

    Pediatric gene therapy trials demand exceptional coordination at the site level, and these frontline insights can help you manage protocol complexity and balance operations with family‑centered care.

  7. Why Cell And Gene Therapy Has Not Reached More Patients — And Why Clinical Operations Is The Bridge 5/29/2026
  8. Ethical & Regulatory Considerations For Pediatric Gene Therapy 5/28/2026

    Understanding risk thresholds, consent requirements, and IRB expectations early can prevent redesign, reduce delays, and improve trial feasibility for vulnerable patient populations

  9. 5 Operational Gaps To Avoid CGT Patient Risks 5/27/2026

    Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.

  10. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.